Amarin Corporation plc welcomed Michael Kalb to its senior management team last week as its SVP and CFO.
"I am very happy to become a part of the Amarin team," Kalb said. "The company has made great progress recently in increasing awareness of Vascepa and its clinical profile. I am excited both by Vascepa's revenue growth and its large potential upside and look forward to working with the Amarin team to help build upon the company's success and drive shareholder value."
Amarin specializes in cardiovascular health.
Kalb has an extensive background as a financial executive and CPA. At his previous position with Taro Pharmaceutical Industries Ltd., he was the CFO and chief accounting officer. His background also includes serving as a director of the Accounting and Financial Consulting Group at Huron Consulting Group Inc. and more than 10 years with Ernst & Young LLP.
"We are delighted to welcome Mike to our team and look forward to leveraging his extensive experience and leadership capabilities as we continue to grow our commercial business and work toward the completion of our cardiovascular outcomes study," Amarin President and CEO John Thero said. "Mike's broad, global business and pharmaceutical experience will further strengthen our executive, financial and operational capabilities as we continue our commercial growth and work toward expanding our business in the future."
Alerts Sign-up